|
1）Schwartz RH. T cell anergy. Annu Rev Immunol. 2003; 21: 305-34
|
|
|
|
2）Wells AD. New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J Immunol. 2009; 182: 7331-41
|
|
|
|
|
|
3）Nurieva RI, et al. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity. 2010; 32: 670-80
|
|
|
|
|
|
4）Zheng Y, Delgoffe GM, Meyer CF, et al. Anergic T cells are metabolically anergic. J Immunol. 2009; 183: 6095-101
|
|
|
|
|
|
5）Chappert P, Schwartz RH. Induction of T cell anergy: integration of environmental cues and infectious tolerance. Curr Opin Immunol. 2010; 22: 552-9
|
|
|
|
|
|
6）Maeda Y, Nishikawa H, Sugiyama D, et al. Detection of self-reactive CD8(+) T cells with an anergic phenotype in healthy individuals. Science. 2014; 346: 1536-40
|
|
|
|
|
|
7）Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunityʼs roles in cancer suppression and promotion. Science. 2011; 331: 1565-70
|
|
|
|
|
|
8）Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol. 2006; 24: 175-208
|
|
|
|
|
|
9）Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004; 4: 1
|
|
|
|
|
|
10）Lesokhin AM, Callahan MK, Postow MA, et al. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med. 2015; 7: 280sr281
|
|
|
|
|
|
11）Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161: 205-14
|
|
|
|
|
|
12）Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371: 2189-99
|
|
|
|
|
|
13）Rizvi NA, Hellmann MD, Synder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124-8
|
|
|
|
|
|
14）Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T-Cell unresponsiveness in vitro and in vivo. J Exp Med. 1987; 165: 302-19
|
|
|
|
|
|
15）Harding FA, Mcarthur JG, Gross JA, et al. CD28-mediated signaling co-stimulates murine T-cells and prevents induction of anergy in T-cell clones. Nature. 1992; 356: 607-9
|
|
|
|
|
|
16）Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009; 9: 324-37
|
|
|
|
|
|
17）Sitkovsky MV, Ohta A. The ʻdangerʼ sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. 2005; 26: 299-304
|
|
|
|
|
|
18）Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30: 531-64
|
|
|
|
|
|
19）Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010; 11: 7-13
|
|
|
|
|
|
20）Wing K, et al. CTLA-4 control over Foxp3＋ regulatory T cell function. Science. 2008; 322: 271-5
|
|
|
|
|
|
21）Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160: 48-61
|
|
|
|
|
|
22）Schadendorf D, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015; 33: 1889-94
|
|
|
|
|